Conference Coverage

AZD8871 delivered significant bronchodilation in two-week study


 

REPORTING FROM ATS 2018


The most common adverse events for patients in all three treatment groups were headache (21.4%) and worsening of COPD-related symptoms (14.3%). No dose-dependence was observed with any adverse event, including serious adverse events and/or those leading to discontinuation.

AstraZeneca, the developer of AZD8871, sponsored the study. Dr. Singh reported being a consultant to and receiving research support from AstraZeneca and numerous other pharmaceutical companies.

SOURCE: Singh, D., et al, Abstract 7708, ATS 2018.

Next Article: